Managing EGFR-Mutated Non-Small-Cell Lung Cancer in Today’s Clinic: Expert Answers to Frequently Asked Questions
- Author
- Ryan Gentzler MD MS, Jonathan Riess MD MS
- Published
- Wed 28 Sep 2022
- Episode Link
- https://oncologypodcast.simplecast.com/episodes/faqs-on-egfr-mutated-nsclc-DIH_CdfY
In this episode, Ryan D. Gentzler, MD, MS, and Jonathan Riess, MD, MS, answer audience questions on managing EGFR-mutated non-small-cell lung cancer (NSCLC) from a live meeting series. The episode includes expert insights on:
• Identifying patients who may benefit the most from adjuvant osimertinib
• Testing for EGFR mutations in early-stage NSCLC
• Critical importance of getting molecular test results before starting immunotherapy
• Monitoring cardiac toxicity in patients receiving osimertinib
• Key ongoing trials in EGFR-mutated NSCLC for patients with newly diagnosed disease and following progression on osimertinib
Presenters:
Ryan D. Gentzler, MD, MS
Associate Professor
Division of Hematology/Oncology
Department of Medicine
University of Virginia
Thoracic Medical Oncologist
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia
Jonathan Riess, MD, MS
Associate Professor
Department of Internal Medicine/Hematology-Oncology
University of California, Davis
Medical Director, Thoracic Oncology
University of California, Davis Comprehensive Cancer Center
Sacramento, California
Link to full program:
https://bit.ly/3DZGzSO
